Considerable interest has been generated from the results of recent clinical trials using smoothened (SMO) antagonists to inhibit the growth of hedgehog (HH) signaling-dependent tumors. This interest is tempered by the discovery of SMO mutations mediating resistance, underscoring the rationale for developing therapeutic strategies that interrupt HH signaling at levels distinct from those inhibiting SMO function. Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to blockade of the HH pathway upstream of SMO, at the level of HH ligand processing. Individually, the use of different lentivirally delivered shRNA constructs targeting two functionally distinct HH-processing proteins, skinny hedgehog (SKN) or dispatched-1 (DISP-1), in NSCLC cell lines produced similar decreases in cell proliferation and increased cell death. Further, providing either an exogenous source of processed HH or a SMO agonist reverses these effects. The attenuation of HH processing, by knocking down either of these gene products, also abrogated tumor growth in mouse xenografts. Finally, we extended these findings to primary clinical specimens, showing that SKN is frequently overexpressed in NSCLC and that higher DISP-1 expression is associated with an unfavorable clinical outcome. Our results show a critical role for HH processing in HH-dependent tumors, identifies two potential druggable targets in the HH pathway, and suggest that similar therapeutic strategies could be explored to treat patients harboring HH ligand-dependent cancers.
INTRODUCTION
The hedgehog (HH) family of secreted proteins, consisting of sonic (SHH), indian and desert HH, is broadly active during development as a morphogen, and in adults is critical for the maintenance of a variety of tissues. 1, 2 Consistent with this critical physiological role regulating proliferation, differentiation and apoptosis, aberrant HH signaling is also evident in a large range of human tumors. 3, 4 In such tumors, HH pathway activation results from noncanonical activation of GLI transcription factors, activating mutations in downstream effectors or from increased expression of HH ligands. 3, 4 HH ligands elicit their effects by binding to their receptor, patched-1 (PTCH-1), 5, 6 which in turn relieves PTCH-1-mediated repression of smoothened (SMO). 7, 8 SMO goes on to activate downstream targets by regulating the levels and processing of the GLI family of transcription factors: GLI-1, GLI-2 and GLI-3. 1, 9 Encouragingly, inhibiting the HH pathway with the SMO antagonist Vismodegib (GDC-0449) has had success in clinical trials as a targeted therapy, and many other SMO antagonists are being studied for activity against various solid tumors. [10] [11] [12] There are, however, already reports of clinical relapses associated with GDC-0449 refractory SMO mutations, demonstrating a need for alternative, functionally distinct targets in the HH pathway. 13, 14 HH proteins undergo a series of processing steps before the secretion of the fully active protein. Initially these are translated as a B45-kDa preprotein containing a signal peptide, an aminoterminal domain and a carboxy-terminal domain. 15, 16 As HH traverses the secretory pathway, the carboxy-terminal domain catalyzes an intra-molecular cleavage reaction that results in the addition of cholesterol to the newly created carboxy-terminus of the amino-terminal domain. 16 The amino-terminus of this is further modified by the addition of a second lipid, palmitate, 17 in a reaction catalyzed by the palmitoyl-transferase skinny hedgehog (SKN, alternatively called hedgehog acyltransferase). [18] [19] [20] [21] [22] Palmitoylation of HH is necessary for ligand activity, with various lipid modifications increasing the activity of recombinant SHH 40-to 160-fold. 23, 24 This dual-lipid-modified HH is transported to the cell surface where its release is regulated by the activity of dispatched-1 (DISP-1), a 12-pass transmembrane domain protein with homology to resistance-nodulation-division permeases.
Mice engineered to lack DISP-1 [26] [27] [28] or SKN 29 function are embryonic-lethal, and display early embryonic phenotypes reminiscent of SMO null mice. 30 Together, these observations underscore the critical role of HH processing in canonical, liganddependent HH signaling.
In non-small cell lung carcinoma (NSCLC), ligand-dependent HH signaling promotes proliferation and tumorigenesis in vitro and in vivo. [31] [32] [33] [34] We, and others, reported frequent constitutive HH pathway activation in primary human NSCLC tumors; an observation recapitulated in tumors derived from transgenic mice overexpressing cyclin-E in the lung. We further demonstrated that two shRNA specifically targeting GLI-1, but not a scramble control, were able to significantly reduce the growth of NSCLC xenografts in vivo, 31 consistent with HH signaling being critical for tumorigenesis. In vitro, the expression of HH target genes increased when NSCLC cells were transfected with SHH and decreased when HH ligand expression was knocked down. 31 Together, these results demonstrated that NSCLC cells harbor a functionally intact HH pathway, both producing active ligand and responding to it. Based on this prior work, we hypothesized that blocking HH signaling upstream of SMO would attenuate NSCLC growth. Here, we present results showing that disrupting HH biogenesis reduces NSCLC proliferative capacity in vitro and the growth of such tumors in vivo. These findings support the autocrine role of HH signaling in NSCLC, and demonstrate the existence of two previously unrecognized druggable targets upstream of SMO.
RESULTS
The HH acyltransferase SKN regulates HH activity To explore a potential role for SKN as a therapeutic target in HHdependent tumors we isolated its cDNA, and used a plasmid expressing this cDNA to verify its functional role in regulating HH activity. We transfected HEK cells with a plasmid expressing wtSHH, or a mutant of SHH in which the palmitate acceptor Cys 17 was mutated to a Ser (SHHC24S), with or without a plasmid expressing SKN. These cells were subsequently incubated with 3 Hpalmitate, followed by immunoprecipitation of SHH, separation of these immunoprecipitates by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and fluorography to determine the degree of SHH palmitoylation. Co-transfection of plasmids expressing SKN with wtSHH, but not SHHC24S, increased the palmitoylation of SHH, confirming the activity of our SKN construct (Figure 1a ). SHH potency in conditioned media (CM) isolated from HEK cells transfected with a plasmid expressing wtSHH, along with different amounts of a plasmid expressing SKN or an empty vector control, was measured to estimate changes in SHH activity. These various CMs were assayed using cells that stably express a HHresponsive luciferase reporter construct (SHH-Light2 cells). 35 Cotransfection of plasmids expressing SKN with wtSHH increased the potency of SHH in a dose-dependent manner (Figure 1b) , consistent with SKN having a pivotal role in HH activity.
As a tool to determine the importance of SKN for SHH activity, we next evaluated the ability of distinct SKN specific, lentivirally Figure 1 . The Hedgehog acyltransferase SKN regulates HH activity. (a) SKN overexpression increased the palmitoylation of wtSHH, but not a mutated form, SHHC24S, in which the acceptor cysteine was mutated to a serine. HEK cells transfected with the indicated constructs were metabolically labeled with 3 H-palmitate. Lysates were collected and subjected to immunoprecipitation with an anti-SHH antibody. The same membrane was also immunoblotted (IB) with an anti-SHH antibody. (b) Co-expression of SKN with SHH in HEK cells increased the potency of SHH in the CM. SHH potency was assessed by normalizing CM activity (SHH-Light2 cell assay) to the amount of SHH protein in the CM. Values were normalized to a pcDNA control. (c) The ability of four SKN-specific shRNA to knockdown endogenous SKN was determined by transducing H23 cells with the indicated shRNAs. Lysates were collected and SKN was immunoprecipitated (IP) with an anti-SKN antibody (SKN2883) or rabbit immunoglobulin G as a control. IPs were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by IB using a second anti-SKN antibody (SKN2884). IB of input lysates with an anti-GAPDH antibody verified normalization. (d) SKN was knocked down in SHH-I cells, which secrete high levels of active SHH, with the indicated shRNA and knockdown efficiency assessed by qRT-PCR. GAPDH expression was used as an internal control and results were normalized to a pLKO.1 control. (e) This knockdown of SKN reduced the potency of SHH in the CM compared with a pLKO.1 empty vector control. Error bars represent s.e.m. of three independent experiments. The asterisks (*) denote a statistically significant change (*Pp0.05, **Pp0.01 and ***Pr0.001) vs control (pcDNA or pLKO.1).
delivered, shRNA to knockdown SKN levels. Knockdown of endogenous SKN protein was confirmed by immunoprecipitating SKN (antibody: SKN2883) from the lysates of H23 cells transduced with SKN-specific shRNA (Figure 1c) , then immunoblotting these immunoprecipitates with a second anti-SKN antibody (antibody: SKN2884). The specificity of these anti-SKN antibodies was validated using a MYC-tagged SKN construct (Supplemental Figures S1a, b) . The two most active SKN shRNAs were evaluated for their ability to knockdown endogenous SKN mRNA levels and affect SHH potency in cells that stably express SHH (SHH-I cells). 36 Knockdown of SKN in these cells was verified by quantitative realtime-PCR (qRT-PCR; Figure 1d ). When the CM from these transduced cells was assayed with SHH-Light2 cells we observed reduced SHH potency compared with the CM from cells transduced with a virus expressing a scramble control shRNA (Figure 1e ). Together, these results validate that SKN palmitoylates SHH 22 and that this palmitoylation is a key determinant of SHH activity. 23, 24 SKN is necessary for the proliferation of NSCLC cells We previously characterized the critical role HH signaling has in human and mouse NSCLC cell lines, using two distinct shRNA targeted to numerous positive acting components of the HH signaling pathway, as well as several SMO antagonists, to attenuate their proliferation and tumorigenicity. 31, 32 Consequently, we decided to use these well-characterized NSCLC cell lines to explore the importance of key HH-processing regulators to the viability of such HH-dependent cell lines. We individually knocked down SKN levels with two different shRNAs in human A549, HOP62, U1752, H23, H522 and murine ED1 33, 37 NSCLC cells, and estimated their proliferation relative to a shScramble control using a Cell Titer-Glo assay (Figures 2a, b) . We observed a reduction in cellular proliferation upon knocking down SKN levels, relative to transduction with control shRNA, and this reduction occurred in all human and mouse NSCLC cell lines tested. To confirm the reduced proliferation observed in the Cell Five days post transduction with the indicated shRNA, cell death and number were assayed simultaneously using a LDH cytotoxicity assay. Released LDH divided by total LDH measures cell death, while total LDH measures total cell number. A representative experiment is shown and error bars represent s.e.m. of four technical replicates. (e) Knockdown of SKN reduced the colony forming capacity of A549 cells. A total of 500 cells transduced with the indicated shRNA were plated in 100-mm dishes and allowed to grow for 3 weeks, at which point colonies were stained and quantified. Error bars represent s.e.m. of three independent experiments, unless otherwise indicated. The asterisk (*) denotes a statistically significant change (*Pp0.05, **Pp0.01 and ***Pp0.001) vs control (shScramble).
Titer-Glo assay we tested BrdU incorporation, a more direct measure of cellular proliferation, in A549 and Hop62 cells transduced with SKN-specific shRNA. The number of BrdUpositive cells observed after reduction of SKN levels was significantly decreased compared with the shScramble control (Figure 2c ), confirming a decrease in the rate of proliferation. Similar results were obtained using an 3-(4,5-dimethyl-2-thiazolyl) 2,5-diphenyl-2H-tetrazolium bromide (MTT) assay where we further validated our results using three additional negative controls or two extra SKN-specific shRNAs (Supplemental Figure S2a) .
We speculated that decreases in proliferation observed upon reduction of SKN levels might in part result from increased cell death. We therefore knocked down SKN and measured the release of the cytoplasmic protein lactate dehydrogenase (LDH) into CM, a commonly used indicator of cell death. 38 Using this assay we observed a significant increase in cell death in response to reduced SKN levels, and this increase was observed using two distinct SKN-specific shRNA in two different NSCLC cell lines (Figure 2d ). Moreover, knockdown of SKN in A549 cells led to an activation of the apoptosis effector caspase: caspase-3, suggesting that the observed cell death is driven by apoptosis (Supplemental Figure S4a) . As a more direct measurement of cell viability, we performed a limiting dilution clonal growth assay. 39 The clonal growth of A549 cells was almost completely abrogated when transduced with SKN-specific shRNA, but not with a shScramble control (Figure 2e and Supplemental S2b). Taken together, these results indicate that SKN is critical for the proliferation of NSCLC lines and that loss of SKN can result in cell death, consistent with our previous work suggesting that HH signaling has roles in both the proliferation and survival of NSCLC cells. 31, 32 SKN is required for HH pathway activity in NSCLC cells As this is the first description of a critical role for HH processing in cancer, we next wanted to determine whether the observed cytotoxic/cytostatic effects of SKN knockdown were due to inhibition of ligand-dependent HH signaling. To assess HH pathway activity, we examined the expression of two wellaccepted HH target genes, GLI-1 and PTCH-1, by qRT-PCR. 1, 9 Knockdown of SKN resulted in significant reductions in the expression of GLI-1 and PTCH-1 in A549 ( Figure 3a ) and Hop62 ( Figure 3b ) cells, relative to cells transduced with a shScramble control. In addition, ED1 cells selected to stably express one of two distinct SKN-specific shRNA had significantly lower HH target gene expression compared with ED1 cells stably expressing a shScramble control (Figure 3c ). Knockdown of SKN in A549 cells also reduced the levels of GLI-1 ( Figure 3d ) and cyclin-D1 proteins (Figure 3e ), both of which are commonly used biomarkers of the HH signaling pathway. 1, 40 These results confirm that HH ligand processing also regulates HH pathway activity in NSCLC lines. DISP-1 is required for NSCLC proliferation, and the oncostatic effect of disrupting ligand processing is HH specific Although SKN function is primarily linked to the function of HH proteins, 18 Drosophila SKN also appears to regulate the activity of a palmitoylated form of epidermal growth factor. 41 Thus, it remains possible that while SKN can regulate HH activity in NSCLC cells, its effect on the viability of cancer cells might be due to it acting on some other signaling protein. To further demonstrate the importance of HH processing to cancer cell proliferation, we examined the role of a second HH-processing protein, DISP-1, 25 in NSCLC viability. We again used a lentiviral driven approach to knockdown DISP-1 in NSCLC cell lines. Knockdown of DISP-1 was observed at the mRNA level (Figures 4a, b ), and at the protein level, as determined using a novel DISP-1-specific antibody (Figure 4c and Supplemental Figure S1c ). As was observed when knocking down SKN, knocking down DISP-1 with multiple different shRNA resulted in significant reductions in HH target genes in both A549 (Figure 4a ) and Hop62 (Figure 4b ) cells. Knockdown of DISP-1 also abrogated the release of SHH into CM whereas knockdown of SKN did not affect SHH secretion (Supplemental Figure S4b) , consistent with their respective roles in SHH processing. [23] [24] [25] DISP-1 knockdown was also accompanied by a decreased number of viable cells, as measured by MTT reduction (Supplemental Figure S2a) . To again determine whether the decrease in cell number observed upon reducing DISP-1 levels was due to a fall in proliferation we transduced NSCLC cell lines with DISP-1-specific shRNA and measured BrdU incorporation. Two distinct DISP-1 shRNA caused a significant reduction in the proliferation of these cancer cell lines (Figure 4d ). As we observed with SKN knockdown, reduction of DISP-1 levels also resulted in increased release of LDH into CM (Figure 4e ), and cleavage of the apoptosis effector caspase, caspase-3 (Supplemental Figure S4a) , both of which are consistent with an increase in apoptotic cell death. In addition, shDISP transduction abrogated the clonogenic growth of A549 cells (Figure 4f and Supplemental Figure S2b) . These results were similar to those observed in NSCLC cells following SKN knockdown.
To further establish a link between reduced HH processing and the observed cytostatic/cytotoxic effects of inhibiting SKN and DISP-1 function, we used an exogenous source of lipid-modified SHH, 36 reasoning that such a form of SHH would bypass the processing defects of these NSCLC cells. We added purified, lipid modified, SHH to the media of shSKN-or shDISP-transduced NSCLC cells and then measured their viability. Purified lipidmodified SHH was indeed able to rescue cell viability in a statistically significant manner ( Figure 4g) ; however, the presence of the detergent required to keep the lipid-modified SHH in solution limited the amount of SHH we could effectively add back to the processing defective NSCLC cells. Despite this limitation significant rescue was observed. We were additionally able to rescue cell viability using the SMO agonist purmorphamine 42 ( Figure 4h ). These results are consistent with the attenuated cell viability observed upon knockdown of SKN or DISP-1 being due to a disruption of ligand-dependent HH signaling.
HH processing is required for NSCLC growth in vivo We next sought to elucidate the in vivo significance of these findings using two distinct mouse models of NSCLC. To explore the role of SKN in a syngeneic FVB mouse model of NSCLC, 37 we transduced green fluorescent protein (GFP)-expressing ED1 cells with either a scramble control shRNA or one of two previously validated SKN-specific shRNA. Although the majority of these cells died, we were able to select surviving polyclonal stable lines that expressed reduced levels of SKN (Figure 3c ). These cell lines were injected into the tail vein of syngeneic FVB mice. After 4 weeks, lung tissue was harvested, sectioned and stained for GFP expression. A blinded investigator then quantified GFP-positive lesions. Significantly fewer lesions were observed in the lungs of animals injected with cells expressing reduced levels of SKN (Figure 5a) .
A second in vivo NSCLC model, consisting of transplanting human NSCLC cells into an immunocompromised mouse as a xenograft, 31 was also used to assess the role HH processing has in human NSCLC. A549 cells were transduced with either a scramble, one of two SKN specific, or one of two DISP-1-specific shRNA. These cells were injected into the flanks of nude mice and tumor volume measured twice weekly for 5 weeks. Tumor formation and histology was verified by hematoxylin and eosin staining and was scored by a board certified lung pathologist (Dr Pablo A Bejarano, data not shown). The mean tumor volume of A549 xenografts transduced with either SKN or DISP-1-specific shRNA was reduced in a statistically significant manner, compared with cells transduced with a scramble shRNA (Figures 5b, c) . These results suggest a critical role for SKN and DISP-1 in NSCLC growth.
HH-processing gene products are overexpressed in human NSCLCs and are associated with an unfavorable clinical outcome To further investigate the role of HH processing in human NSCLC, we examined the expression of SKN and DISP-1 in 58 pairs of tumor and matched normal tissue using an oligonucleotide microarray. 43 The majority of these patient samples expressed higher levels of SKN in the tumor vs the adjacent normal tissue (Figure 6a and Supplemental S3a). A smaller subset of tumors also overexpressed DISP-1 (Figure 6b ). We also directly analyzed the expression of SKN and DISP-1 in a commercially available cDNA array consisting of 24 pairs of matched lung tumor and normal lung tissue. The same patterns of expression of SKN and DISP-1 observed in the microarray were also abnormal by qRT-PCR analysis (Figures 6c, d ). To further confirm these results, we again directly analyzed the expression of SKN and DISP-1 in 6 pairs of tumor and matched normal tissue harvested locally by our group (Supplemental Figure S3b) . We performed immunohistochemistry on these same samples to determine the levels of SHH, which we then compared with SKN and DISP-1 mRNA expression. Although the sample size was too small to draw any statistical conclusions, tumors with increased SKN expression are the ones with the strongest SHH staining (Supplemental Figure S3c) .
We mined publically available data sets consisting of tumor microarray data matched with clinical outcome (overall and progression-free survival), to assess the clinical significance of SKN and DISP-1 expression. There was no correlation seen between SKN expression and clinical outcome (data not shown), however, increased DISP-1 expression correlated with decreased recurrencefree and overall survival in the two data sets analyzed (Figures 6e, f and data not shown). These results point to a critical and clinically relevant role for HH ligand processing in NSCLC tumorigenesis, progression and recurrence.
DISCUSSION
The HH signaling pathway has a critical role in the growth and maintenance of a wide variety of human tumors. 3, 4 This, coupled with the recent early success of GDC-0449 in clinical trials [10] [11] [12] and our results, indicates that pharmacological inhibition of the HH pathway would be therapeutically beneficial in clinical NSCLC. Indeed, various SMO inhibitors are currently undergoing trials for the treatment of a wide array of solid tumors, including NSCLC. 10, 11, 44 There are, however, already reports of drug resistant SMO mutations, 13, 14 highlighting the importance of finding alternative druggable targets within the HH pathway. Considerable work has been focused on the HH pathway downstream of SMO, with compounds having successfully been developed that antagonize GLI transcription factors. 45 Conversely, potential drug targets upstream of SMO have remained, for the most part, unexplored. 46 We show here that disruption of the HH signaling pathway upstream of SMO, at the level of HH ligand processing, inhibits HH signaling and subsequently attenuates tumorigenesis. As high-level HH activity is dependent on lipid modification, 23, 24 we first disrupted HH processing by reducing the levels of SKN, the enzyme responsible for the amino-terminal palmitoylation of HH. 18, 22 This resulted in reduced HH pathway activity in NSCLC cell lines, as demonstrated by both decreased target gene expression and reduced steady-state levels of two protein biomarkers. Attenuation of HH signaling was accompanied Hedgehog processing in cancer J Rodriguez-Blanco et al (f ) Knockdown of DISP-1 reduced the colony forming capacity of A549 cells. A total of 500 cells transduced with the indicated shRNA were plated in 100-mm dishes and allowed to grow for 3 weeks, at which point colonies were stained and quantified. (g) Exogenous lipid-modified SHH can partially rescue the proliferative defects of both A549 and HOP62 cells transduced with the indicated constructs. Cells were transduced with two SKN specific, two DISP-1 specific or a scramble shRNA control. Twenty-four hours post transduction, viral media was substituted with fresh media containing purified lipid-modified SHH or SHH purification buffer at the same concentration. After 4 days, cell number was measured by MTT assay and normalized to the appropriate shScramble control. A representative experiment is shown and error bars represent s.e.m. of six technical replicates. (h) The SMO agonist purmorphamine can rescue the proliferative defects of A549 cells transduced with the indicated constructs. A549 cells were transduced with the indicated scramble, SKN or DISP-1 shRNAs. Viral media was removed 24 h later and was substituted with fresh media containing either 15 mM purmorphamine or vehicle (dimethyl sulfoxide) control. Four days post transduction cell number was measured using a MTT assay and normalized to cells transduced with a shScramble control. A representative experiment is shown and error bars represent s.e.m. of six technical replicates. Error bars represent s.e.m. of three independent experiments (unless otherwise indicated). The asterisk (*) denotes a statistically significant change (*Pp0.05, **Pp0.01 and ***Pp0.001) vs control (shScramble unless otherwise indicated by a bar).
Hedgehog processing in cancer J Rodriguez-Blanco et al by decreased cell viability in vitro and reduced tumor growth in both a xenograph and a syngeneic in vivo model of NSCLC. Strikingly, similar effects were observed when levels of the protein required for the release of cholesterol-modified HH, DISP-1 25 were reduced. Combined, these results suggest that the effects observed upon reducing SKN or DISP-1 levels result from inhibition of HH signaling, as reducing the levels of two otherwise unrelated components of the HH biogenesis pathway decreases NSCLC cell viability. Furthermore, consistent with this decreased cell viability being caused by reduced HH activity, providing these cells with either exogenous dually lipid-modified SHH or the SMO agonist purmorphamine resulted in a significant rescue of cell viability.
Both SKN and DISP-1 are located on chromosome 1q, a region that is frequently amplified in NSCLC 47 and associated with increased tumor recurrence. 48 Together with our other data, this prompted us to examine expression patterns of these genes in clinical specimens of NSCLC. We found that the majority of clinical NSCLC samples expressed higher levels of SKN in malignant tissue than in matched normal one, implying a critical role for SKN in lung tumorigenesis. DISP-1 expression was increased in a smaller subset of lung tumors. Interestingly, DISP-1, but not SKN, expression correlates with decreased overall and recurrence-free survival, suggesting that in situations where SKN is overexpressed release of the processed ligand may be a rate-limiting step in HHdependent tumors.
The role HH has in human cancer has been controversial. Initially, results gained from the study of inherited forms of PTCH-1 deletions, and from a variety of mouse models engineered to lack PTCH-1, implicated basal cell carcinoma, medulloblastoma and rhabdomyosarcoma as the predominant HH pathway-dependent tumors. [49] [50] [51] [52] [53] [54] This work was further supported by the identification of PTCH-1 or SMO mutations in sporadic forms of these tumors. 55, 56 It was later shown that the HH signaling pathway, as well as the ligands themselves, were enriched in numerous other types of human cancer. [57] [58] [59] [60] [61] [62] [63] Furthermore, the viability of cells derived from these cancers was reduced in vitro when treated with SMO antagonists. 36, 64, 65 Where examined, no mutations in the common components of the HH signaling pathway were found in these HHligand-dependent cancers. [57] [58] [59] [60] [61] [62] [63] Such results suggested that the HHdependent tumor cell lines functioned, for the most part, in an autocrine-like manner, producing and responding to HH ligands themselves. It was later found that SMO antagonists could function nonspecifically in vitro, and that in vivo HH secreted from tumor cells acted directly on the stroma to regulate tumor growth in a paracrine-like manner. 66 More rigorous in vitro analyses now indicate that the ability of HH to function in a paracrine or autocrine manner may be context dependent. 31, 67, 68 Our previous work revealed that some subset of NSCLC cells, human or mouse, produce and respond to HH ligands in an autocrine manner. 31, 33 Such data were obtained using SMO inhibitors in vitro and using lentiviral-mediated knockdown of numerous, distinct components of the HH signaling pathway. These results were further supported by immunohistochemistry analyses of primary human NSCLC samples, which showed SHH and GLI-1 enriching predominantly in epithelial tumor cells. Importantly, the localization of these proteins in primary NSCLC samples was further validated using in situ mRNA hybridization experiments. The work presented here is also consistent with a paracrine-like role for HH ligands in NSCLC, as a reduction in HH processing reduces the viability of NSCLC cells in vitro and in vivo. Unfortunately, the paucity of antibodies to SKN or DISP-1 capable of detecting these proteins in primary NSCLC specimens leaves us unable to complete further immunohistochemistry analyses. Even so, our results demonstrate the feasibility and potential benefit of targeting more proximal signaling elements within the HH pathway, and imply that similar therapeutic strategies could be explored to inhibit the growth of HH ligand-dependent cancers.
MATERIALS AND METHODS
NSCLC cell lines A549: human alveolar adenocarcinoma (squamous in nature), HOP62: human lung adenocarcinoma, H23: human lung adenocarcinoma (epithelial morphology), H522: human lung adenocarcinoma (epithelial morphology) and U1752: squamous bronchiolar epithelial were obtained and cultured as previously described. 32 ED-1: mouse lung adenocarcinoma, 33, 37 derived from the lung tumors of transgenic mice that express cyclin-E driven by the human SURFACTANT-C promoter, SHHLight2, 35 SHH-I 36 and HEK cells (293T or Bosc23) 69 were maintained as described. All expression constructs were in the pcDNA3.1 vector. The WT human SHH expression vector was a gift from Dr Cliff Tabin. The SKN and SKN-MYC-HIS constructs were cloned from human cDNA (H23 cells) and were validated by sequencing. All lentiviral shRNA constructs are in the (for shSKN) and 1.00 Â 10 6 (for shDISP) A549 cells transiently transduced with the indicated shRNAs were injected into the flanks of nude mice (shScramble n ¼ 13, shSKN2 n ¼ 7, shSKN3 n ¼ 6, shDISP n ¼ 9 and shDISP n ¼ 8) and tumor volume was measured biweekly. Error bars represent s.e.m.. The asterisk (*) denotes a statistically significant change (*Pp0.05, **Pp0.01 and ***Pp0.001) vs control (shScramble).
pLKO.1 vector and were either purchased from Open Biosystems (Lafayette, CO, USA) or engineered into the pLKO.1 TRC cloning vector directly. 70 Lentivirus was packaged as per manufacturer's instructions (Open Biosystems) and cells were transduced as previously described. 31 All plasmids were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as per manufacturer's instructions.
Assays
HEK cells were transfected with plasmids expressing wtSHH or SHHC24S and SKN, and SHH palmitoylation assayed by [9,10- 3 H] palmitic acid (Perkin Elmer, Newton, MA, USA) incorporation as previously described. 69 CM activity was assayed by SHH-Light2 cell assay as before 71, 72 as a measure of SHH activity, which is normalized to SHH expression in the CM (determined (e) Higher DISP-1 expression is associated with reduced recurrence free survival. A publically available dataset (GSE8894) consisting of microarray profiles of 138 NSCLC cases and an associated clinical survival database (recurrence-free survival) was mined to find correlations between DISP-1 expression and recurrence-free survival. Lung cancers were separated into tertiles based on DISP-1 expression, and the top third compared with the bottom third. (f) Higher DISP-1 expression is associated with reduced survival in a second publically available dataset (GSE10245) consisting of microarray profiles of 58 NSCLC cases and an associated clinical outcome database (overall and progression-free survival). This dataset was analyzed in the same manner as for GSE10245. P-values reported are from a one-tailed log-rank (Mantel-Cox) test.
by immunoblot) to determine SHH potency. Immunoprecipitations were performed as described, 73 and levels of the indicated proteins were determined by immunoblot analysis. 72 The expression of the indicated genes was measured by quantitative qRT-PCR as described. 39 NSCLC cells were transduced with shRNA, and 5 days later cell number was measured in two independent assays. Cell viability was assessed by monitoring ATP concentrations using the Cell Titer-Glo assay (Promega, Madison, WI, USA) according to the manufacturer's instructions (except for ED1 cells, which were assayed as described), 74 or by monitoring mitochondrial activity by the reduction of MTT to Formazan as before. 75 Proliferation was assessed by incubating cells with 10 mM BrdU (BD, San Jose, CA, USA) for 4 h, and immunostaining was performed as previously described. 76 At least six independent fields were counted per experimental condition under the Â 20 objective of an Olympus IX7I microscope (Olympus, San Diego, CA, USA). Cell death was assessed by measuring LDH activity using the Tox-7 In Vitro Toxicology Assay Kit (Sigma, St Louis, MO, USA) as specified by the manufacturer. The ratio between released LDH in the CM and the total LDH was used as a measure of cell death, while the total LDH value is of cell proliferation. Clonal growth was assessed as described 39 with these following modifications: Twenty-four hours post transduction with the indicated constructs, media was replaced with media containing 2.5 mg/ml puromycin for 24 h, at which point cells were trypsinized and plated in 100-mM dishes at a density of 500 cells/plate. After 3 weeks, colonies were stained with crystal violet and visible colonies were quantified. In order to rescue growth defects resulted from decreased HH processing, NSCLC cells transduced with control, SKN-or DISP-1-specific shRNA were supplemented with either dual-lipid-modified SHH (purified from SHH-I cells 36 in a 0.1% NP-40 buffer) at a final concentration of 2.5 nM or purification buffer alone (final NP-40 concentration in media was 0.0003%), and was replaced every 2-3 days. Alternatively, cells were treated with 15 mM of the SMO agonist purmorphamine or vehicle control (dimethyl sulfoxide). Cell viability was assessed by MTT assay 5 or 4 days, respectively, post transduction.
Antibodies
A total of three New Zealand barrier bred rabbits were injected with a SKNspecific KLH-conjugated antigenic peptide: KVSREHEEELDQEFELETDTLFG. Test bleeds were analyzed by enzyme-linked immunosorbent assay, and the terminal bleeds from the best two rabbits were affinity purified to yield two polyclonal rabbit anti-SKN antibodies: SKN2883 and SKN2884. For DISP-1 antibody production this same protocol was followed to purify the DISP-Q5253 polyclonal antibody. The immunogenic sequence used for DISP-1 was the following: VEGFVHPITHIHHCPCLQGRVKPAGMQNSLPR NFFLHPVQHIQAQEKIGKTNVHSLQRSIEEHLPKMAEPSSFVCRSTGSLLKTCCDPE NKQRELCKNRDVSNLESSGGTENKAGGKVELSLSQTDASVNSEHFNQNEPKVLFN HLMGEA. Antibodies for SKN were tested by immunoblotting lysates from HEK cells transfected with either pcDNA3.1 empty vector or a plasmid expressing SKN-MYC-HIS (Supplemental Figures S1a, b) , and by immunoblotting (using SKN2884) SKN2883 immunoprecipitates from the lysates of H23 cells transduced with a Scramble control or four different SKN-specific shRNA (Figure 1c) . The antibody for DISP-1 was tested by inmunoblotting lysates of A549 (Figure 4c ) and H23 cells (Supplemental Figure S1c) transduced with shScramble and shGFP as controls, as well as four different DISP-1-specific shRNA. The GLI-1 antibody was custom made by a contract laboratory. 39 Commercially available antibodies used were as follows: SHH (H-160) and a-tubulin (Santa Cruz, Delaware, CA, USA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Ambion, Austin, TX, USA), BrdU, cleaved caspase-3 and cyclin-D1 (Cell Signaling, Danvers, MA, USA), MYC (9e10, Covance, Princeton, NJ, USA) and appropriate horseradish peroxidase or Alexa Fluor-conjugated secondary antibodies (Invitrogen).
In vivo experiments
All mouse work was conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at the university where it was performed. GFP-positive ED1 cells were selected with 2.5 mg/ml puromycin to stably express the indicated shRNA then injected into the tail vein of syngeneic FVB mice and tumor formation assessed as described.
37
A549 xenografts were performed as previously described 31 with the following modifications: for the shSKN xenografts 1.25 Â 10 6 cells were injected, and for the shDISP xenografts 1 Â 10 6 cells were injected.
Clinical expression and survival studies
Clinical expression of SKN and DISP-1 was assessed in three different ways: A commercially available tumor cDNA array consisting of 24 matched pairs of human lung tumor and normal tissues was purchased and used per manufacturer's instructions (TissueScan Lung Cancer cDNA Array IV, Origene Technologies, Rockville, MD, USA), 6 pairs of locally obtained matched pairs of human lung tumor and normal tissue were analyzed by qRT-PCR, and a set of 58 tumor/normal pairs from NSCLC patients was analyzed using a custom Agilent (Palo Alto, CA, USA) whole-genome oligonucleotide microarray as previously described. 43 Gene expression and patient survival data for two independent tumor datasets (accession numbers GSE8894 and GSE10245) were obtained from the Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/geo/) and normalized using GCRMA. 77 GSE8894 consists of 138 post resection NSCLC tumors with information on recurrence-free survival, 78 whereas GSE10245 consists of 58 high-grade NSCLC tumors with both recurrence-free and overall survival data. 79 The gene expression values used here were determined from array data, using the standard Affymetrix U133 Plus 2.0 (Affymetrix, Santa Clara, CA, USA) protocol (data were pre-processed using GCRMA normalization). For each data set, patients were grouped into tertiles based on expression levels (that is: low, middle and high) of SKN (probeset ID ¼ 219687_at) or DISP-1 (probeset ID ¼ 228184_at), and survival times of patients with expression values in the lowest tertile compared with those of patients whose expression was ranked in the highest tertile. The tertile cutoff was chosen as B33% of patients tested, which showed increased expression of DISP-1 in tumor vs normal tissue.
Statistical analysis
Results shown represent the mean of at least three independent experiments±s.e.m., unless otherwise noted. For the microarray data, normalized log 10 expression values for each probe were compared between the normal and tumor samples using a two-tailed Wilcoxon matched-pairs signed-rank test. Significance was tested using an unpaired one-tailed Student's t-test, except for the Kaplan-Meier survival curves, which were tested by a Mantel-Cox test. Differences were considered significant in the following way: *Pp0.05, **Pp0.01 and ***Pp0.001.
